Interferon-α before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure

Blood

Volumn 94, Issue 11, 1999, Pages 3668-3677

  Hehlmann, Rüdiger ^a   Hochhaus, Andreas ^b   Kolb, Hans Jochem ^b   Hasford, Jörg ^b   Gratwohl, Alois ^b   Heimpel, Hermann ^b   Siegert, Wolfgang ^b   Finke, Jürgen ^b   Ehninger, Gerhard ^b   Holler, Ernst ^b   Berger, Ute ^b   Pfirrmann, Markus ^b   Muth, Alexander ^b   Zander, Axel ^b   Fauser, Axel A ^b   Heyll, Axel ^b   Nerl, Christoph ^b   Hossfeld, Dieter K ^b   Löffler, Helmut ^b   Pralle, Hans ^b   Queißer, Wolfgang ^b   Tobler, Andreas ^b   more..

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BUSULFAN; HYDROXYUREA;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033485291     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.11.3668.423a31_3668_3677     Document Type: Article

References (24)

1. Silver RT, Woolf SH, Hehlmann R, Appelbaum F, Anderson J, Bennett C, Goldman JM, Guilhot F, Kantarjian HM, Lichtin AE, Talpaz M, Tura S: The benefits and harms of treatments for chronic myeloid leukemia, Blood 94:1517, 1999
2. Goldman JM, Szydlo R, Horowitz MM, Gale RP, Ash RC, Atkinson K, Dicke KA, Gluckman E, Herzig RH, Marmont A, Masaoka T, McGlave PB, Messner H, O'Reilly RJ, Reiffers J, Rimm AA, Speck B, Veum-Stone JA, Wingard JR, Zwaan FE, Bortin MM: Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 82:2235, 1993
3. Beelen DW, Graeven U, Elmaagacli AH, Niederle N, Kloke O, Opalka B, Schaefer UW: Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood 85:2981, 1995
4. Morton AJ, Gooley T, Hansen JA, Appelbaum FR, Bruemmer B, Bjerke JW, Clift R, Martin PJ, Petersdorf EW, Sanders JE, Storb R, Sullivan KM, Woolfrey A, Anasetti C: Association between pretransplant interferon-α and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. Blood 92:394, 1998
5. Holler E, Schleuning M, Ledderose G, Mittermüller H, Wilmanns W, KoIb HJ: IFN alpha prior to allogeneic BMT in patients with chronic myelogenous leukemia. Ann Hematol 73:A96, 1996 (abstr)
6. Giralt SA, Kantarjian HM, Talpaz M, Rios MB, Del Giglio A, Andersson BS, Przepiorka D, Deisseroth AB, Champlin RE: Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia. J Clin Oncol 11:1055, 1993
7. Tomas JF, Lopez-Lorenzo JL, Requena MJ, Aguilar R, Steegmann JL, Camara R, Alegre A, Arranz R, Figuera A, Fernandez-Ranada JM: Absense of influence of prior treatment with interferon on the outcome of allogeneic bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant 22:47, 1998
8. Zuffa E, Bandini G, Bonini A, Santucci MA, Martinelli G, Rosti G, Testoni N, Zaccaria A, Tura S: Prior treatment with alpha-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia. Haematologica 83:231, 1998
9. Shepherd P, Richards S, Allan N: Survival after allogeneic bone marrow transplantation (BMT) in patients randomised into a trial of IFN-α versus chemotherapy. No significant adverse effect of prolonged IFN-α administration. Blood 86:94a, 1995 (abstr, suppl 1)
10. Horowitz MM, Giralt S, Szydlo R, Goldman J, Veum-Stone J, for the International Bone Marrow Transplantation Registry (IBMTR): Effect of prior interferon therapy on outcome of HLA-identical sibling bone marrow transplants for chronic myelogenous leukemia (CML) in first chronic phase. Blood 88:682a, 1996 (abstr, suppl 1)
11. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queisser W, Löffler H, Hochhaus A, Heinze B, Georgii A, Bartram CR, Griesshammer M, Bergmann L, Essers U, Falge C, Queisser U, Meyer P, Schmitz N, Eimermacher H, Walther F, Fett W, Kleeberg UR, Käbisch A, Nerl C, Zimmermann R, Meuret G, Tichelli A, Kanz L, Tigges FJ, Schmid L, Brockhaus W, Tobler A, Reiter A, Perker M, Emmerich B, Verpoort K, Zankovich R, von Wussow P, Prümmer O, Thiele J, Buhr T, Carbonell F, Ansari H, and the German CML Study Group: Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 84:4064, 1994
12. Hehlmann R, Heimpel H, Hossfeld DK, Hasford J, KoIb HJ, Löffler H, Pralle H, Queisser W, Hochhaus A, Tichelli A, Fett W, Schmitz N, Reiter A, Griesshammer M, Pfeifer W, Bäumler M, Kamp T, Tobler A, Eimermacher H, Kuse R, Berger U, Ansari H, and the German CML Study Group: Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). Bone Marrow Transplant 17:S21, 1996 (suppl 3)
13. The Italian Cooperative Study Group on Chronic Myeloid Leukemia: Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330:820, 1994
14. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, Tso CY, Braun TJ, Clarkson BD, Cervantes F, Rozman C: Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 63:789, 1984
15. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans J, Alimena G, Steegmann JL, Ansari H: A new prognostic score for the survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst 90:850, 1998 (Internet: http://www.pharmacoepi.de for the calculation of the new score)
16. Gratwohl A, Hermans J, Goldman JM, Frassoni F, Devergie A, Carreras E, Kolb HJ, Gahrton G, Arcese W, Vernant JP, Ruutu T, de Witte T, van Rhee F, Apperley J, for the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT): Risk assessment for patients with chronic myeloid leukemia before allogeneic blood or marrow transplantation. Lancet 352:1087, 1998
17. Lausen B, Schumacher M: Maximally selected rank statistics. Biometrics 48:73, 1992
18. Altman DG, Lausen B, Sauerbrei W, Schumacher M: Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86:829, 1994
19. Hehlmann R: A chance of cure for every patient with CML? N Engl J Med 338:980, 1998
20. Hansen JA, Gooley TA, Martin PJ, Appelbaum F, Chauncey TR, Clift RA, Petersdorf EW, Radich J, Sanders JE, Storb RF, Sullivan KM, Anasetti C: Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia in chronic phase. N Engl J Med 338:962, 1998
21. Gale RP, Hehlmann R, Zhang M-J, Hasford J, Goldman JM, Heimpel H, Hochhaus A, Klein JP, Kolb HJ, McGlave PB, Passweg JR, Rowlings PA, Sobocinski KA, Horowitz MM, and the German CML Study Group: Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. Blood 91:1810, 1998
22. Santucci MA, Soligo D, Pileri S, Zuffa E, Testoni N, Tura S: Interferon-alpha effects on stromal compartment of normal and chronic myeloid leukemia hematopoiesis. Leuk Lymphoma 11:113, 1993
23. Aman MJ, Rudolf G, Goldschmitt J, Aulitzky WE, Lam C, Huber C, Peschel C: Type-I interferons are potent inhibitors of interleukin-8 production in hematopoietic and bone marrow stromal cells. Blood 82:2371, 1993
24. Petricoin EF, Ito S, Williams BL, Audet S, Stancato LF, Gamero A, Clouse K, Grimley P, Weiss A, Beeler J, Finbloom DS, Shores EW, Abraham R, Larner AC: Antiproliferative action of interferon-α requires components of T-cell-receptor signalling. Nature 390:629, 1997